Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials (Q33830120)

29 July 2017

0 references

Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials (English)

1 reference

29 July 2017

0 references

Magee LA

1

1 reference

29 July 2017

Elran E

2

1 reference

29 July 2017

Bull SB

3

1 reference

29 July 2017

Logan A

4

1 reference

29 July 2017

Koren G

5

1 reference

29 July 2017

1 January 2000

1 reference

European Journal of Obstetrics Gynecology and Reproductive Biology

29 July 2017

1 reference

29 July 2017

88

1 reference

29 July 2017

1

1 reference

29 July 2017

15-26

1 reference

National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Treatment of hypertension in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

The relation between treatment benefit and underlying risk in meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Why sources of heterogeneity in meta-analysis should be investigated

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

The statistical basis of meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

A measure to aid in the interpretation of published clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Methods for combining randomized clinical trials: strengths and limitations.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Atenolol in essential hypertension during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Management of pregnancy-induced hypertension with pindolol--comparative study with methyldopa

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Propranolol in Pregnancy Three Year Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Malignant ventricular arrhythmias in eclampsia: a comparison of labetalol with dihydralazine.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Intravenous terbutaline and simultaneous β1-blockade for advanced premature labor

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2899%2900113-X

7 January 2021

10.1016/S0301-2115(99)00113-X

Identifiers

DOI

1 reference

release_giwi5kaumzdk3omc5mjdvymoka

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/giwi5kaumzdk3omc5mjdvymoka

24 November 2022

mapped directly with Wikidata item

1 reference